Takeuchi H, Kobashi K, Yoshida O
Invest Urol. 1980 Sep;18(2):102-5.
We tested the inhibitory power and urinary excretion of several derivatives of hippurohydroxamic acid, including some newly synthesized compounds. m-Methoxyhippurohydroxamic acid (UCD II) strongly inhibited urease activity and high urinary excretion after oral administration to rats. UCD II inhibited the alkalinization of infected urine in vitro and in vivo and prevented bladder stone formation when it was orally administered to rats with urinary tract infection caused by Proteus mirabilis. The clinical application of UCD II to the prevention of pathologic sequelae of urinary infection with urease-producing bacteria awaits evaluation of the safety of the compound.
我们测试了马尿酸异羟肟酸的几种衍生物的抑制能力和尿排泄情况，其中包括一些新合成的化合物。间甲氧基马尿酸异羟肟酸（UCD II）对脲酶活性有强烈抑制作用，给大鼠口服后尿排泄量较高。UCD II在体外和体内均能抑制感染尿液的碱化，当给感染奇异变形杆菌引起尿路感染的大鼠口服时，可预防膀胱结石形成。UCD II在预防产脲酶细菌引起的泌尿系统感染的病理后遗症方面的临床应用有待对该化合物的安全性进行评估。
